DURHAM, N.C., May 24, 2023 (GLOBE NEWSWIRE) — Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary conditions, today announced results from studies of AER-901 (inhaled imatinib) that support progression into a Phase 2 clinical trial in both pulmonary […]
Tag: Aerami
Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer
DURHAM, N.C., Nov. 18, 2021 (GLOBE NEWSWIRE) — Aerami Therapeutics, Inc. (the “Company”), a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the appointment of Barry Deutsch as chief financial officer effective November 15, 2021. “Barry is a seasoned financial executive who brings […]
Aerami Therapeutics Signs License Agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. for Aerami’s PAH (pulmonary arterial hypertension) Drug Device Combination in China
DURHAM, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) — Aerami Therapeutics, Inc. (“Aerami” or the “Company”) a clinical stage biopharmaceutical company developing inhaled therapies to treat severe respiratory and chronic diseases today announces the signing of an exclusive license and development agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. (“Chance”) to develop […]



